Gloved scientist handles syringe vial in biotech lab with DNA overlay, hinting GLP-1 drug innovation. Key Points Eli Lilly leads the GLP-1 market while advancing late-stage drugs in Alzheimer’s, oncology, and cardiovascular disease. Viking Therapeutics offers a high-upside GLP-1 challenger supported by strong trial data and institutional ownership. Biogen provides exposure to neurodegenerative disease breakthroughs at a valuation below its historical averages. Interested in Biogen Inc.? Here are five ...